Mild To Moderate Plaque Psoriasis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant,

Mild To Moderate Plaque Psoriasis emerging therapies such as INBRX-109, TIBSOVO (ivosidenib), and others are expected to boost the Mild To Moderate Plaque Psoriasis Market in the upcoming years.

DelveInsight has launched a new report on "Mild To Moderate Plaque Psoriasis - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the Mild To Moderate Plaque Psoriasis, historical and forecasted epidemiology as well as the Mild To Moderate Plaque Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our sample report @ https://www.delveinsight.com/report-store/mild-to-moderate-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Mild To Moderate Plaque Psoriasis Market Report:

The Mild-to-Moderate Plaque Psoriasis Market is projected to grow at a significant CAGR during the forecast period (2023-2032).
In 2024, China approved Jinlixi, a monoclonal antibody that neutralizes interleukin-17A, for treating adults with moderate-to-severe plaque psoriasis.
Approved by the FDA in September 2022, Sotyktu is an oral therapy targeting tyrosine kinase 2 (TYK2). It offers a novel mechanism of action for adults with moderate-to-severe plaque psoriasis.
The FDA approved biosimilars such as ustekinumab-kfce (Yesintek) and ustekinumab-stba (Steqeyma) in December 2024, providing more treatment options for plaque psoriasis.
Johnson & Johnson's oral drug, icotrokinra, met its primary goals in a late-stage trial for moderate-to-severe plaque psoriasis, showing significant skin clearance in 64.7% of patients after 16 weeks.
In December 2021, the U.S. Food and Drug Administration (FDA) expanded the indication for Otezla to include adult patients with plaque psoriasis across all severities-mild, moderate, and severe. This approval made Otezla the first and only oral treatment approved for such a broad patient population.
Key pharmaceutical companies, including AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, and others, are actively developing therapies for mild-to-moderate plaque psoriasis treatment.
Approximately 78% of psoriasis patients have mild to moderate forms of the disease (≤10% body surface area involvement), with mild cases (≤3% BSA) accounting for 50% of all cases. In contrast, only 2% of patients experience extensive psoriasis affecting more than 50% of their body surface.
A 2021 online cross-sectional survey conducted in the U.S. by Gupta et al. included 175 patients with mild-to-moderate plaque psoriasis. Among them, 67.4% were female, with a median age of 55 years and an average disease duration of 10.8 years since diagnosis.
Promising Mild To Moderate Plaque Psoriasis pipeline therapies in various stages of development include Otezla, SGX302, AKP02/AKVANO, and others.
Key benefits of the Mild To Moderate Plaque Psoriasis market report:
Mild To Moderate Plaque Psoriasis market report covers a descriptive overview and comprehensive insight of the Mild To Moderate Plaque Psoriasis Epidemiology and Mild To Moderate Plaque Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Mild To Moderate Plaque Psoriasis market report provides insights on the current and emerging therapies.
Mild To Moderate Plaque Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Mild To Moderate Plaque Psoriasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Mild To Moderate Plaque Psoriasis market.

Got queries? Click here to know more about the Mild To Moderate Plaque Psoriasis Market Landscape https://www.delveinsight.com/sample-request/mild-to-moderate-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mild To Moderate Plaque Psoriasis Overview

Psoriasis is a chronic, immune-mediated skin disorder that accelerates the skin cell growth cycle, causing cells to multiply up to 10 times faster than normal. This leads to the formation of thick, red patches with silvery scales, which are often intensely itchy. These patches commonly appear on the elbows, knees, scalp, lower back, face, palms, and soles, but can also affect the nails, mouth, and other areas.

The most prevalent form, plaque psoriasis, accounts for approximately 80% of all cases. Diagnosis involves examining the skin, scalp, and nails for characteristic signs. In some cases, a biopsy is performed, where a dermatopathologist analyzes skin cells under a microscope to confirm the presence of psoriasis. Dermatologists typically use a punch biopsy for this procedure.

To know more about the Mild To Moderate Plaque Psoriasis treatment algorithms, visit: https://www.delveinsight.com/report-store/mild-to-moderate-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mild To Moderate Plaque Psoriasis Treatment Market

The American Academy of Dermatology (AAD) treatment guidelines recommend that managing localized mild-to-moderate plaque psoriasis should start with patient education and topical corticosteroids, either alone or in combination with coal tar or calcipotriene.

If the initial treatment proves ineffective or loses effectiveness over time, anthralin or tazarotene, either alone or with corticosteroids, may be introduced as a second-line option.

For cases where disease control remains challenging or psoriasis becomes more widespread, phototherapy-with or without adjunctive medications like psoralen or retinoids-may be necessary.

Mild To Moderate Plaque Psoriasis Market Outlook

Topical therapies are the first-line treatment for localized plaque psoriasis, though light therapy is also widely used for mild-to-moderate cases. Common light-based treatments include whole-body or targeted UVB (broad and narrow band), photochemotherapy (PUVA), home phototherapy, and LASER.

Systemic treatments include acitretin, methotrexate, cyclosporine, tacrolimus, hydroxyurea, 6-thioguanine, mycophenolate, fumaric acid esters, apremilast, and biologic agents. Among biologics, etanercept, adalimumab, infliximab, secukinumab, ustekinumab, tildrakizumab, and ixekizumab are approved for plaque psoriasis.

According to DelveInsight, the Mild-to-Moderate Plaque Psoriasis Market across the 7MM is projected to undergo significant changes during the 2019-2032 study period.

Know more about the rising Mild To Moderate Plaque Psoriasis market, visit: https://www.delveinsight.com/sample-request/mild-to-moderate-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mild To Moderate Plaque Psoriasis Emerging Drugs

SGX302: Soligenix
AKP02/AKVANO: Lipidor AB

Mild To Moderate Plaque Psoriasis Marketed Drugs

Otezla: Amgen

Scope of the Mild To Moderate Plaque Psoriasis Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Mild To Moderate Plaque Psoriasis Companies: AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, and others
Key Mild To Moderate Plaque Psoriasis Therapies: Otezla, SGX302, AKP02/AKVANO, and others
Mild To Moderate Plaque Psoriasis Therapeutic Assessment: Mild To Moderate Plaque Psoriasis current marketed and Mild To Moderate Plaque Psoriasis emerging therapies
Mild To Moderate Plaque Psoriasis Market Dynamics: Mild To Moderate Plaque Psoriasis market drivers and Mild To Moderate Plaque Psoriasis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Mild To Moderate Plaque Psoriasis Unmet Needs, KOL's views, Analyst's views, Mild To Moderate Plaque Psoriasis Market Access and Reimbursement

To get detailed insights on the scope of our Mild To Moderate Plaque Psoriasis market report, visit: https://www.delveinsight.com/report-store/mild-to-moderate-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Mild To Moderate Plaque Psoriasis Patient Share (%) Overview at a Glance
5. Mild To Moderate Plaque Psoriasis Market Overview at a Glance
6. Mild To Moderate Plaque Psoriasis Disease Background and Overview
7. Mild To Moderate Plaque Psoriasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Mild To Moderate Plaque Psoriasis
9. Mild To Moderate Plaque Psoriasis Current Treatment and Medical Practices
10. Unmet Needs
11. Mild To Moderate Plaque Psoriasis Emerging Therapies
12. Mild To Moderate Plaque Psoriasis Market Outlook
13. Country-Wise Mild To Moderate Plaque Psoriasis Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Mild To Moderate Plaque Psoriasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Mild To Moderate Plaque Psoriasis Market Outlook 2032 https://www.delveinsight.com/sample-request/mild-to-moderate-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Mild To Moderate Plaque Psoriasis Pipeline Insights, DelveInsight

"Mild To Moderate Plaque Psoriasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Mild To Moderate Plaque Psoriasis market. A detailed picture of the Mild To Moderate Plaque Psoriasis pipeline landscape is provided, which includes the disease overview and Mild To Moderate Plaque Psoriasis treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.